Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Blocking FGL2 protein may offer new approach to treating brain cancer

Blocking FGL2, a protein known to promote cancer, may offer a new strategy for treating brain cancer, according to a study at The University of Texas MD Anderson Cancer Center.

14 May 2015

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.

13 May 2015

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen.

13 May 2015

Australian researchers discover rogue germinal centre B cells that trigger autoimmune disease

Australian researchers believe they have discovered a group of cells that trigger autoimmune disease, as well as the molecular 'trigger guard' that normally holds them in check.

13 May 2015

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

11 May 2015

Raising lupus awareness: an interview with Professor Ramsey-Goldman, MD

Lupus is a chronic, autoimmune disease, with many different symptoms so it is hard to diagnose. It affects each person differently and it has an unpredictable disease course with flare ups and quiet time. Some patients describe lupus as if they are riding a roller coaster with blinders on because they cannot always tell when they will feel well or sick...

11 May 2015

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options.

11 May 2015

Cardiff scientists develop novel anti-cancer stem cell compound

Cardiff University scientists have developed a novel anti-cancer stem cell agent capable of targeting aggressive tumour forming cells common to breast, pancreas, colon and prostate cancers.

7 May 2015

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Heather Wakelee, MD, is the recipient of the 2015 ECOG-ACRIN Young Investigator Award, the ECOG-ACRIN Cancer Research Group announced today. Dr. Wakelee is associate professor of medicine in the Division of Oncology at the Stanford University School of Medicine in Stanford, Calif.

7 May 2015

Study sheds light on long-hidden link between chronic high blood sugar and disruption of mitochondria

Scientists at Johns Hopkins say they've discovered a cause-and-effect link between chronic high blood sugar and disruption of mitochondria, the powerhouses that create the metabolic energy that runs living cells. The discovery, reported online in Proceedings of the National Academy of Sciences on April 27, sheds light on a long-hidden connection and, they say, could eventually lead to new ways of preventing and treating diabetes.

6 May 2015

Protein Sciences, CTH@H to provide Flublok vaccine to home health and hospice agencies in Connecticut

Protein Sciences Corporation, along with The Connecticut Association for Healthcare at Home, announced a new partnership today that will bring Flublok influenza vaccine to home health and hospice agencies across the state. As a new affinity partner of CTH@H, Protein Sciences will make Flublok available to CTH@H member agencies for the 2015/16 flu season.

5 May 2015

Bio-Techne's net sales increase 19% to $114.2 million in third quarter 2015

Bio-Techne Corporation today reported its financial results for the third quarter ended March 31, 2015.

From ProteinSimple 5 May 2015

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cells are taken from the patient’s blood and then modified using lentivirus, adenovirus or RNA electroporation.

From Beckman Coulter Life Sciences - Flow Cytometry 5 May 2015

Pre-POINT trial raises hope for Type 1 diabetes prevention

Giving oral insulin to children at genetic high risk of diabetes stimulates a regulatory immune response without inducing hypoglycaemia, show the findings of the Pre-POINT study.

1 May 2015

High Throughput ChIP-seq Assay for Genome-wide Protein-DNA Analysis

Chromatrap®, a business unit of Porvair Sciences, has published a new application note that describes how Chromatrap® ChIP-seq assays now enable unbiased, genome-wide understanding of protein-DNA regulatory networks...

From Chromatrap® - Porvair Sciences Ltd 30 Apr 2015

Texas Biomed scientists awarded NIH grant to develop potential HPV-based HIV vaccine

Scientists at Texas Biomedical Research Institute have begun work on a nearly $3.4 million study funded by the National Institutes of Health over the next four years to create an attenuated, or weakened, virus that is a hybrid of the papilloma virus and the human immunodeficiency virus, with the potential to jumpstart a body's immune response to develop antibodies against both viruses.

30 Apr 2015

ITIM-containing receptor crucial for development of acute myeloid leukemia

UT Southwestern Medical Center scientists have discovered that a certain class of receptors that inhibit immune response are crucial for the development of acute myeloid leukemia (AML), the most common acute leukemia affecting adults.

30 Apr 2015

Cytokine GM-CSF likely plays important role in MS

Multiple sclerosis (MS) is caused by immune cells that activate a cascade of chemicals in the brain, attacking and degrading the insulation that keeps neuronal signals moving. These chemicals, called cytokines, drive the inflammation in the brain, attracting more immune cells, and causing the debilitating disease marked by loss of neurological function.

30 Apr 2015

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

The European Commission has licensed Avastin in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. Until now, the treatment has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF).

28 Apr 2015

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Intarcia Therapeutics, Inc. today announced the closing of a $225 million synthetic royalty financing with an equity conversion option at a $5.5 billion Company valuation. Plans are to use these funds to accelerate the initiation of additional head-to-head comparative and switch studies of ITCA 650 vs. leading oral and injectable type 2 diabetes therapies.

28 Apr 2015

Antibody News and Research

Further Reading

Blocking FGL2 protein may offer new approach to treating brain cancer

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Soligenix, Emergent BioSolutions sign development agreement

Australian researchers discover rogue germinal centre B cells that trigger autoimmune disease

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Raising lupus awareness: an interview with Professor Ramsey-Goldman, MD

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Cardiff scientists develop novel anti-cancer stem cell compound

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Study sheds light on long-hidden link between chronic high blood sugar and disruption of mitochondria

Protein Sciences, CTH@H to provide Flublok vaccine to home health and hospice agencies in Connecticut

Bio-Techne's net sales increase 19% to $114.2 million in third quarter 2015

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

Pre-POINT trial raises hope for Type 1 diabetes prevention

High Throughput ChIP-seq Assay for Genome-wide Protein-DNA Analysis

Texas Biomed scientists awarded NIH grant to develop potential HPV-based HIV vaccine

ITIM-containing receptor crucial for development of acute myeloid leukemia

Cytokine GM-CSF likely plays important role in MS

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News